Premium
Frontline treatment of epithelial ovarian cancer
Author(s) -
GOH Jeffrey,
MOHAN G Raj,
LADWA Rahul,
ANANDA Sumitra,
COHEN Paul A,
BARONHAY Sally
Publication year - 2015
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12449
Subject(s) - epithelial ovarian cancer , medicine , bevacizumab , cytoreductive surgery , ovarian cancer , oncology , adjuvant , chemotherapy , stage (stratigraphy) , intraperitoneal chemotherapy , adjuvant chemotherapy , cancer , breast cancer , biology , paleontology
This is a contemporaneous review of the frontline treatment of epithelial ovarian cancer (EOC), specifically on the importance of optimal surgical cytoreductive surgery, the pivotal role of platinum‐based adjuvant chemotherapy (which encompasses intraperitoneal and dose‐dense regimens) and the emergence of neo‐adjuvant chemotherapy. Additionally, the benefit of concurrent and maintenance bevacizumab in the suboptimally debullked stage III and stage IV EOC setting is also reviewed. The article also discusses the increasing importance of prognostic and predictive molecular biomarkers in the future management of EOC.